Evaluation of spirometry as a parameter of response to chemotherapy in advanced lung cancer patients: A pilot study

Simple item page
dc.contributor.authorAggarwal, Deepaken_US
dc.contributor.authorMohapatra, Prasanta Ren_US
dc.contributor.authorJanmeja, Ashok Ken_US
dc.contributor.authorSaini, Varinderen_US
dc.date.accessioned2020-11-18T10:08:10Z
dc.date.available2020-11-18T10:08:10Z
dc.date.issued2020-09
dc.description.abstractContext: Spirometry is an important tool to monitor treatment response in diseases such as chronic obstructive pulmonary disease and asthma. However, there is lack of evidence to support its application to evaluate response to chemotherapy in advanced lung cancer. It might be a useful adjunct to the imaging-based response evaluation which lacks functional assessment of lungs. Aims: The study was conducted to evaluate the change in spirometry in lung cancer patients after chemotherapy and to find its correlation with change in physical tumor size. Subjects and Methods: Sixty-two advanced lung cancer patients who were eligible for palliative chemotherapy were enrolled. Baseline tumor size evaluation using Response Evaluation Criteria in Solid Tumor (RECIST)-based scoring system, and spirometry was done. Four cycles of double agent (platinum doublets) chemotherapy were administered, after which treatment response was evaluated. Repeat spirometry was analyzed and correlated with changes in physical tumor size. Results: Twenty-five patients showed a response (all partial response) to four cycles of chemotherapy. Small cell carcinoma showed a better response rate than non-small cell carcinoma (78% vs. 39%). There was statistically significant improvement in forced expiratory volume in 1 (FEV1) (P = 0.01) and forced vital capacity (P = 0.03) in responders as compared to nonresponders. Change in FEV1 showed a statistically significant correlation with the change in tumor size (RECIST score) (r = –0.34; P = 0.04). Conclusions: Improvement in spirometry correlates with the tumor response as judged using RECIST criteria after chemotherapy. Further studies with bigger sample size are required to consolidate the resultsen_US
dc.identifier.affiliationsDepartment of Pulmonary Medicine, Government Medical College and Hospital, Chandigarh, Indiaen_US
dc.identifier.affiliationsDepartment of Pulmonary Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, Indiaen_US
dc.identifier.affiliationsDepartment of Pulmonary Medicine, Government Medical College and Hospital, Chandigarh, Indiaen_US
dc.identifier.affiliationsDepartment of Pulmonary Medicine, Government Medical College and Hospital, Chandigarh, Indiaen_US
dc.identifier.citationAggarwal Deepak, Mohapatra Prasanta R, Janmeja Ashok K, Saini Varinder. Evaluation of spirometry as a parameter of response to chemotherapy in advanced lung cancer patients: A pilot study. Journal of Cancer Research and Therapeutics. 2020 Sep; 16(4): 788-792en_US
dc.identifier.issn0973-1482
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/213703
dc.languageenen_US
dc.publisherWolters Kluwer India Pvt. Ltd.en_US
dc.relation.issuenumber4en_US
dc.relation.volume16en_US
dc.source.urihttps://dx.doi.org//10.4103/jcrt.JCRT_919_17en_US
dc.subjectLung functionen_US
dc.subjectnon‑small cell lung canceren_US
dc.subjectresponse evaluation criteria in solid tumoren_US
dc.titleEvaluation of spirometry as a parameter of response to chemotherapy in advanced lung cancer patients: A pilot studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcrt2020v16n4p788.pdf
Size:
695.36 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Cancer Research and Therapeutics